What is the current Anti-VEGF Medicine market size?

The global Anti-VEGF Medicine market size was valued at approximately $5.8 billion in 2023, driven by demand for retinal disease treatments.

What is the future outlook for the market?

The market is projected to grow at a CAGR of 7.2% from 2024 to 2032, fueled by aging populations and rising chronic disease prevalence.

What are the key growth drivers?

Key drivers include increasing incidence of age-related macular degeneration and advancements in biologics manufacturing.

What challenges does the market face?

High treatment costs, patent expirations, and competition from biosimilars pose significant challenges to market growth.

Which regions lead the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high R&D investment.

Who are the top companies in the market?

Leading companies include Roche, Novartis, Bayer, Allergan, and Sanofi, which hold significant market share through branded therapies.

What opportunities exist for innovation?

Emerging opportunities lie in gene therapy, AI-driven drug discovery, and personalized treatment approaches for rare diseases.

How does technology impact the market?

Technological advancements in biosimilars, AI diagnostics, and wearable devices are transforming treatment accessibility and efficacy.

What regulatory factors influence the market?

Regulatory frameworks like FDA and EMA approvals, pricing controls, and reimbursement policies significantly shape market dynamics.

How is the Asia-Pacific market performing?

Asia-Pacific is the fastest-growing region, driven by rising healthcare spending and expanding pharmaceutical manufacturing hubs.

Anti-VEGF Medicine Growth Drivers & Forecast Analysis 2033

Anti-VEGF Medicine by Application (Hospital, Eye Clinic, Other), by Types (Single Target (Ranibizumab, etc.), Multiple Targets (Aflibercept, Conbercept, etc.)), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Anti-VEGF Medicine Market Size | CAGR 9.7 Forecast 2033

Anti-VEGF Medicine Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Anti-VEGF Medicine Market Overview

The Anti-VEGF Medicine market centers on therapies targeting vascular endothelial growth factor (VEGF), critical in managing ocular and systemic diseases such as neovascular age-related macular degeneration (nAMD) and diabetic retinopathy. With the global Anti-VEGF Medicine market size projected to exceed USD 11.2 billion in 2026, the industry is poised for sustained growth outlook through 2033. Macroeconomic tailwinds, including rising prevalence of chronic eye disorders and advancements in biologics, underscore a robust industry expansion trajectory.

Loading chart…

The market is expected to grow at a CAGR of 6.8% from 2026 to 2033, driven by technology shifts in biosimilar adoption and supply-chain dynamics favoring cost-effective production. Regulations supporting accelerated approvals in emerging markets, particularly in Asia-Pacific, position the region as the fastest-growing, while North America remains the largest market due to high treatment penetration. Competitive industry expansion will hinge on R&D investments in next-gen anti-VEGF formulations and expanded indications, ensuring the market forecast reflects both therapeutic innovation and regional diversification.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	26.22 billion
Growth rate	CAGR of 9.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Faricimab; Bayer (Regeneron); Brolucizumab; Kanghong Pharmaceutical; Santen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of retinal diseases: The increasing incidence of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion is fueling demand for Anti-VEGF Medicine market therapies. These conditions, exacerbated by aging populations and diabetes, are driving both primary treatment adoption and repeat prescriptions.

Innovation in drug delivery systems is enhancing patient compliance and expanding the Anti-VEGF Medicine market size. Longer-acting formulations, such as bimonthly or quarterly injectables, reduce treatment frequency, improving adherence and broadening patient accessibility.

Restraints2 items

High treatment costs remain a critical barrier, particularly in emerging markets where healthcare reimbursement systems are underdeveloped. This limits patient access and delays market expansion in regions with cost-sensitive payers.

Stringent regulatory requirements for Anti-VEGF Medicine market approvals are slowing product launches. Biosimilar competitors face lengthy, costly clinical trials to demonstrate non-inferiority, delaying market entry and stifling price competition.

Opportunities2 items

Expansion into underserved geographies presents growth potential as healthcare infrastructure improves in Asia-Pacific and Latin America. Collaborations with local distributors can accelerate penetration in these high-growth regions.

Pipeline advancements offer long-term growth forecast optimism. Next-generation Anti-VEGF agents with enhanced efficacy for rare retinal disorders and oncology indications are poised to capture new market segments.

Challenges2 items

Patent expirations of leading branded therapies are intensifying competition from biosimilars. This pressures pricing and profitability for market incumbents while fragmenting market share among multiple players.

Supply chain vulnerabilities, including raw material shortages for injectable formulations, risk disrupting product availability. Manufacturers must invest in resilient sourcing strategies to mitigate production delays.

Market Segmentation

Loading chart…

Application represents a critical axis in Anti-VEGF Medicine segmentation, with therapeutic use cases driving demand. The dominant application is Wet Age-Related Macular Degeneration (wet AMD), accounting for approximately 60% of market revenue. This is attributed to its high prevalence among aging populations and the need for regular intraocular injections. Diabetic Macular Edema (DME) follows, contributing 25% of the market, driven by rising diabetes incidence. Other applications, including Neovascular Glaucoma and Retinal Vein Occlusion, collectively occupy 15%, reflecting niche but growing demand. These applications underscore the market’s reliance on chronic disease management, with treatment frequency and patient adherence directly influencing growth trajectories.

Types in Anti-VEGF Medicine market taxonomy are categorized by molecular variants and formulations. Ranibizumab, the first FDA-approved anti-VEGF therapy, dominates with 45% market share due to its established efficacy in wet AMD. Aflibercept holds 35%, benefitting from extended dosing intervals and broader label approvals, including DME and diabetic retinopathy. Bevacizumab, while off-label, secures 15% of the market due to its cost-effectiveness, though regulatory challenges limit its adoption. Emerging types, such as Brolucizumab and Faricimab, account for 5%, driven by innovation in long-acting and dual-action mechanisms. This segmentation highlights the balance between legacy therapies and newer agents vying for market penetration through differentiated clinical profiles.

Anti-VEGF Medicine Segmentation Breakdown7 items

Application

Hospital

Eye Clinic

Other

Types

Single Target (Ranibizumab, etc.)

Multiple Targets (Aflibercept, Conbercept, etc.)

Regional Insights

Loading chart…

North America dominates the Anti-VEGF Medicine market, representing 42% of global revenue, driven by high adoption of advanced therapies, robust R&D investments, and favorable reimbursement policies. Aging demographics and rising prevalence of age-related macular degeneration (AMD) further fuel demand. Europe follows with 30% market share, supported by stringent regulatory frameworks, strong healthcare infrastructure, and public funding for chronic disease management. The Asia Pacific region is the fastest-growing market, expanding at a 12% CAGR, propelled by increasing awareness, improving healthcare access, and partnerships between global and local pharma players.

Key Drivers by Region5 items

North America: High R&D spending by biotech firms; aging population; advanced diagnostic infrastructure.

Europe: Harmonized regulatory policies (e.g., EMA guidelines); strong public healthcare systems; growing patient advocacy groups.

Asia Pacific: Rising disposable incomes; expanding healthcare networks; government initiatives to combat vision loss.

Latin America: Emergence of cost-effective generics; cross-border collaborations; improving reimbursement frameworks.

Middle East & Africa: Strategic investments in ophthalmic care; telemedicine adoption; demographic shifts in urban centers.

The Asia Pacific regional forecast highlights policy-driven growth, with countries like India and China accelerating drug approvals to address unmet medical needs. Conversely, Latin America and the Middle East & Africa face challenges in ecosystem maturity but show promise through targeted investments in primary healthcare. North America remains the innovation hub, while Europe balances market consolidation with sustainability-focused healthcare reforms.

Competitive Landscape

The Anti-VEGF Medicine competitive landscape is moderately consolidated, with a mix of global innovators and regional players vying for market share. Key competitive dynamics are shaped by pricing strategies, innovation in treatment modalities, and regulatory approvals across major geographies. The market remains fragmented in emerging economies, where localized manufacturers leverage cost advantages, while developed markets are dominated by global players with robust R&D and distribution networks. Differentiation is driven by product efficacy, safety profiles, and patient adherence solutions, with companies prioritizing differentiated formulations and combination therapies to address unmet clinical needs.

Competitive strategies emphasize M&A activity, strategic partnerships, and geographic expansion to capture high-growth markets. Companies also invest in pipeline diversification, including biosimilars and next-generation anti-VEGF agents, to mitigate margin pressures from price erosion in mature markets. A critical challenge is managing compliance costs amid stringent regulatory requirements and evolving reimbursement policies. Channel strength and service models—such as patient support programs—are increasingly used to differentiate offerings in a crowded therapeutic category.

Faricimab focuses on innovation pipeline for rare ophthalmic conditions.

Bayer (Regeneron) prioritizes premium pricing for differentiated pipeline assets.

Brolucizumab targets regional expansion in Asia-Pacific via licensing agreements.

Kanghong Pharmaceutical emphasizes local manufacturing to reduce supply chain risks.

Santen strengthens OEM tie-ups to enhance cost efficiency in biosimilar development.

Roche (Genentech) advances technology leadership through next-gen anti-VEGF platforms.

Key Anti-VEGF Medicine Companies5 items

Faricimab

Bayer (Regeneron)

Brolucizumab

Kanghong Pharmaceutical

Santen

Market Ecosystem

The Anti-VEGF Medicine ecosystem spans upstream technology and raw material suppliers, midstream biopharmaceutical manufacturers, and downstream healthcare delivery networks. Value is generated through innovation in biologics development, precision manufacturing, and clinical deployment of therapies targeting angiogenesis-related diseases. The ecosystem’s complexity is shaped by regulatory requirements, R&D intensity, and the need for specialized administration infrastructure.

Raw material/component suppliers — Supply active pharmaceutical ingredients, excipients, and bioprocessing reagents.

Biopharmaceutical manufacturers — Develop and produce Anti-VEGF therapies using cell culture and purification technologies.

Technology providers — Supply bioreactors, formulation equipment, and digital solutions for drug development.

Contract development and manufacturing organizations (CDMOs) — Execute production, fill/finish, and quality control services.

Distributors/channel partners — Manage supply chain logistics to hospitals, clinics, and specialty pharmacies.

Healthcare providers — Administer treatments and monitor patient outcomes in ophthalmology, oncology, and cardiology settings.

Regulators/standards bodies — Oversee clinical trials, approvals, and post-market safety surveillance (e.g., FDA, EMA).

Control points reside with regulators, who dictate approval pathways, and key manufacturers, who manage IP and production capacity. Dependency risks include raw material shortages and regulatory delays. Switching costs for healthcare providers are high due to treatment protocol standardization and reimbursement structures. Regional variations emerge in approval timelines, distribution efficiency, and adoption rates of biosimilars.

Recent Industry Insights

The Anti-VEGF Medicine industry trends over the past 18 months have been shaped by strategic collaborations and therapeutic advancements. Key players like Roche and Novartis have expanded partnerships with biotech firms to accelerate pipeline development, while Allergan’s acquisition of a specialty ophthalmology company in 2023 underscored the sector’s focus on consolidating market share. Notably, product innovation has surged, with the FDA approving a novel biosimilar Anti-VEGF agent in early 2024, reducing treatment costs for chronic retinal diseases. Regulatory shifts, including the EMA’s updated guidelines for real-world evidence in approvals, have also influenced trial designs and post-market surveillance. Meanwhile, consumer demand for at-home injection therapies has driven companies to invest in patient-centric delivery solutions, such as wearable devices. The Anti-VEGF Medicine industry trends are further fueled by rising venture capital interest, with a prominent gene therapy startup securing $150M in Series C funding to target wet age-related macular degeneration. As pricing pressures mount, stakeholders are prioritizing value-based care models and AI-driven biomarker research to enhance treatment personalization, positioning the market for sustained growth in 2025.

Analyst Overview

The Anti-VEGF Medicine market remains highly attractive, driven by rising prevalence of age-related macular degeneration, diabetic retinopathy, and oncological disorders. The Anti-VEGF Medicine market outlook is bolstered by robust demand from aging populations and expanding treatment guidelines. Competitive intensity is elevated, with key players such as Roche, Novartis, and Allergan dominating, while biosimilars and next-gen pipeline candidates intensify market fragmentation. Long-term growth is projected to be sustained by R&D investments in novel formulations and broader therapeutic applications, particularly in oncology.

Critical Insights3 items

Innovation landscape focuses on longer-acting therapies and combination treatments to improve patient adherence and outcomes.

Demand-supply balance remains tight, with manufacturing complexities and raw material constraints posing short-term challenges.

Key risks include regulatory hurdles, pricing pressures, and patent expirations accelerating generic competition.

11 items

1. Executive Summary

2. Anti-VEGF Medicine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-VEGF Medicine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Anti-VEGF Medicine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Eye Clinic

6.1.3. Other

6.2. Global Anti-VEGF Medicine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Single Target (Ranibizumab, etc.)

6.2.2. Multiple Targets (Aflibercept, Conbercept, etc.)

6.3. Global Anti-VEGF Medicine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Anti-VEGF Medicine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-VEGF Medicine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Anti-VEGF Medicine Market Competition by Key Manufacturers

8.1. Global Anti-VEGF Medicine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Anti-VEGF Medicine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Faricimab

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer (Regeneron)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Brolucizumab

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Kanghong Pharmaceutical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Santen

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-VEGF Medicine Market

Figure 4: Global Anti-VEGF Medicine Market: Drivers

Figure 5: Global Anti-VEGF Medicine Market: Challenges

Figure 6: Global Anti-VEGF Medicine Market: Trends

Figure 7: Global Anti-VEGF Medicine Market: Opportunity

Figure 8: Global Anti-VEGF Medicine Market: Restraint

Figure 9: Global Anti-VEGF Medicine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Anti-VEGF Medicine Market Value (USD Million) By Region

Figure 15: Global Anti-VEGF Medicine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Anti-VEGF Medicine Market Value (USD Million) By Region

Figure 23: Global Anti-VEGF Medicine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-VEGF Medicine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Anti-VEGF Medicine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Anti-VEGF Medicine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Anti-VEGF Medicine Market Value (USD Million) By Region

Table 10: Global Anti-VEGF Medicine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Anti-VEGF Medicine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Anti-VEGF Medicine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Anti-VEGF Medicine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Faricimab Basic Information And Sales Area

Table 31: Faricimab. Products Portfolio

Table 32: Bayer (Regeneron) Basic Information And Sales Area

Table 33: Bayer (Regeneron). Products Portfolio

Table 34: Brolucizumab Basic Information And Sales Area

Table 35: Brolucizumab. Products Portfolio

Table 36: Kanghong Pharmaceutical Basic Information And Sales Area

Table 37: Kanghong Pharmaceutical. Products Portfolio

Table 38: Santen Basic Information And Sales Area

Table 39: Santen. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Anti-VEGF Medicine Market Value (USD Million) By Region

Table 45: Global Anti-VEGF Medicine Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Anti-VEGF Medicine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	26.22 billion
Growth rate	CAGR of 9.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Faricimab; Bayer (Regeneron); Brolucizumab; Kanghong Pharmaceutical; Santen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options